PHARNEXT To Present At 4th International Neurotech Investing And Partnering Conference
Published: Sep 29, 2017
PARIS--(BUSINESS WIRE)--Regulatory News:
Pharnext SA (FR00111911287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 4th International Neurotech Investing and Partnering Conference.
The presentation will take place as follows:
- Date: Wednesday, October 4th, 2017
- Time: 4:00pm CEST
- Venue: Wyss Center in Geneva, Switzerland
If you are interested in meeting the Pharnext management team during this event, please send an email to Anne Hennecke at firstname.lastname@example.org.
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Media Relations (Europe)
+33 (0)1 44 54 36 64
Media Relations (U.S.)
+1 212 223 4017